Exact Sciences Stock News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Exact sciences stock. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Exact Sciences Stock Today - Breaking & Trending Today

Exact Sciences to Participate in June Investor Conferences

28.05.2024 - Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company management will participate in the following conferences and invited investors to participate by webcast. William Blair . ....

Sciences On Linkedin , Sciences Corp , Sciences Stock , About Exact Sciences , Exact Sciences , Exact Sciences Stock ,

Exact Sciences Stock, A Cathie Wood Darling, Tumbles On 'Overblown' Growth Concerns

Exact Sciences Stock, A Cathie Wood Darling, Tumbles On 'Overblown' Growth Concerns
biztoc.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from biztoc.com Daily Mail and Mail on Sunday newspapers.

A Cathie Wood , Sciences Stock , Exact Sciences , Exact Sciences Stock , Cathie Wood Darling , Overblown Growth Concerns ,

Exact Sciences Falls 4% On Larger-Than-Feared 4Q Loss

Shares of Exact Sciences Corporation fell 4.4% In Tuesday’s post-market trading after the cancer screening and diagnostic tests provider reported lower-than-expected 4Q earnings. Meanwhile, exact Sciences (EXAS) posted a loss per share of $2.79 during the fourth quarter, which was higher than the $0.22 loss per share expected by analysts. Revenue increased about 58% year-on-year to $466.3 million topping analysts’ estimates of $446.22 million. During the quarter its screening revenue which includes revenue from Cologuard and Biomatrica products rose 9% to $249.7 million. Revenue from COVID-19 testing was $99.1 million. Exact Sciences acquired Base Genomics in 4Q and recorded the acquisition as a $412.6 million charge to R&D expense. For fiscal 2020, the company generated sales of $1.49 billion, up from the $876.29 million posted in 2019. Diluted loss per share came in at $5.61 versus a loss of $0.64 in the comparable year-ago period. Exact Sciences’ CEO Kevin ....

Exact Sciences , Exact Sciences Stock , Cancer Screening , Colorectal Cancer Screening , சரியான அறிவியல் , சரியான அறிவியல் ஸ்டாக் , புற்றுநோய் திரையிடல் , பெருங்குடல் புற்றுநோய் திரையிடல் ,